Your Yourlocation: Home > Clinical study of budesonide formoterol combined with tiotropium bromide(136310-93-5) in the treatment of moderate to severe bronchial asthma

Bronchial asthma is a high clinical incidence of a chronic respiratory disease, and with the deterioration of human living environment, the disease prevalence in recent years, rising year after year. Domestic and foreign scholars pointed out that long-term patients with bronchial asthma to receive standardized treatment, can effectively control asthma attacks, delay the progress of the disease, thereby improving the quality of life of patients. Glucocorticoids and β2 agonists are two commonly used drugs for the treatment of asthma. Budesonide Formoterol is a combination of glucocorticoid and β2 agonist, which can effectively inhibit inflammatory cell activity and decrease Inflammatory factor production, while reducing vascular permeability, improve lung function. Tiotropium bromide(136310-93-5) is a new anticholinergic drug, in recent years in the treatment of respiratory diseases is also more and more widely. Now our hospital using budesonide formoterol, tiotropium bromide in the treatment of moderate to severe bronchial asthma reported as follows.

The subjects were from March 2015 to March 2016 in our hospital 98 patients with moderate to severe bronchial asthma. The bronchodilator test was positive; the FEV1 / FVC after the use of bronchodilator (forced expiratory volume of 1 second / forced vital capacity) was less than 70%; the patients were more likely to respond to bronchial diastolic dysfunction Informed consent was obtained by informed consent. Exclusion criteria: imaging confirmed the presence of pulmonary infection; with severe heart, brain, liver, kidney disease; malignant tumor disease; can not comply with medical treatment. (N = 49). The control group consisted of 21 males and 28 females, aged from 18 to 69 years (mean, 45.87 ± 10.69) years. The average age of the study group was 19 to 70 years (mean, 46.05 ± 9.57 years). The study group included 20 males and 29 females with a history of smoking ranging from 1 to 9 years (3.35 ± 1.24) years. Course of 1 to 7 years, the average (2.75 ± 1.07) years, 28 cases of smoking history. The two groups of the basic situation is close, there is no significant difference (P> 0.05), can be compared.


(1) The control group was treated with budesonide formoterol alone (AstraZeneca AB, Sweden). Inhaled budesonide Formoterol, each time a suction, 2 times a day, continuous treatment for 8 weeks for a course of treatment, a total of two courses of treatment. In this case,

(2) The combined use of budesonide formoterol and tiotropium (Zhejiang Xianju Pharmaceutical Co., Ltd., Zhunzi H20090279). Inhaled tiotropium bromide(136310-93-5), 18μg / time, day 1, continuous treatment for 8 weeks for a course of treatment, a total of two courses of treatment. Inhaled tiotropium bromide(136310-93-5), inhaled tiotropium bromide(136310-93-5), inhaled budesonide formoterol, each 1 suction, 2 times a day.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved